AUROBINDO PHARMA LTD vs DR. REDDY S LABORATORIES

A side-by-side comparison of AUROBINDO PHARMA LTD (AUROPHARMA) and DR. REDDY S LABORATORIES (DRREDDY) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DR. REDDY S LABORATORIES leads AUROPHARMA vs DRREDDY on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

25.41
P/E ratio
24.09
2.39
P/B ratio
2.96
0.25%
Dividend yield
0.59%
₹60.34
EPS
₹50.27

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

10.10%
Return on equity
11.80%
13.00%
Return on capital
14.00%
20.00%
EBITDA margin
19.00%
10.41%
Net margin
12.34%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.63%
Revenue CAGR (3Y)
10.96%
22.02%
Profit CAGR (3Y)
-2.65%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹89,061 Cr
Market cap
₹1.01L Cr
₹33,653 Cr
Revenue
₹33,700 Cr
₹3,503 Cr
Net profit
₹4,158 Cr
0.21
Debt / equity
0.20
AUROBINDO PHARMA LTD
  • ["The company has delivered a poor sales growth of 6.32% over past five years.", "Company has a low return on equity of 10.8% over last 3 years.", "Company might be capitalizing the interest cost"]
DR. REDDY S LABORATORIES
  • + ["Company's working capital requirements have reduced from 85.1 days to 67.8 days"]
  • ["Dividend payout has been low at 13.2% of profits over last 3 years"]
AUROBINDO PHARMA LTD full analysis DR. REDDY S LABORATORIES full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.